Immunotherapeutic Potential of m6A-Modifiers and MicroRNAs in Controlling Acute Myeloid Leukaemia.
TLDR
In this article, the therapeutic potential of m6A-modifiers in controlling haematological disorders, especially acute myeloid leukaemia (AML), was summarized.Abstract:
Epigenetic alterations have contributed greatly to human carcinogenesis. Conventional epigenetic studies have been predominantly focused on DNA methylation, histone modifications, and chromatin remodelling. Epitranscriptomics is an emerging field that encompasses the study of RNA modifications that do not affect the RNA sequence but affect functionality via a series of RNA binding proteins called writer, reader and eraser. Several kinds of epi-RNA modifications are known, such as 6-methyladenosine (m6A), 5-methylcytidine (m5C), and 1-methyladenosine. M6A modification is the most studied and has large therapeutic implications. In this review, we have summarised the therapeutic potential of m6A-modifiers in controlling haematological disorders, especially acute myeloid leukaemia (AML). AML is a type of blood cancer affecting specific subsets of blood-forming hematopoietic stem/progenitor cells (HSPCs), which proliferate rapidly and acquire self-renewal capacities with impaired terminal cell-differentiation and apoptosis leading to abnormal accumulation of white blood cells, and thus, an alternative therapeutic approach is required urgently. Here, we have described how RNA m6A-modification machineries EEE (Editor/writer: Mettl3, Mettl14; Eraser/remover: FTO, ALKBH5, and Effector/reader: YTHDF-1/2) could be reformed into potential druggable candidates or as RNA-modifying drugs (RMD) to treat leukaemia. Moreover, we have shed light on the role of microRNAs and suppressors of cytokine signalling (SOCS/CISH) in increasing anti-tumour immunity towards leukaemia. We anticipate, our investigation will provide fundamental knowledge in nurturing the potential of RNA modifiers in discovering novel therapeutics or immunotherapeutic procedures.read more
Citations
More filters
Journal ArticleDOI
Functions, mechanisms, and therapeutic implications of METTL14 in human cancer
TL;DR: Zhang et al. as discussed by the authors systematically summarized the latest research progress on METTL14 as a new biomarker for cancer diagnosis and its biological function in human tumors and discuss its potential clinical application.
Journal ArticleDOI
Biological Aspects of Inflamm-Aging in Childhood Cancer Survivors
Francesca Rossi,Alessandra Di Paola,Elvira Pota,Maura Argenziano,Daniela Di Pinto,Maria Maddalena Marrapodi,Caterina Di Leva,Martina Di Martino,Chiara Tortora +8 more
TL;DR: In this paper, a review of the possible biological mechanisms involved in the development of inflamm-aging, focusing on immune system alteration, oxidative stress, cellular senescence, and therapeutic strategies is presented.
Journal ArticleDOI
The Role of N6-Methyladenosine in the Promotion of Hepatoblastoma: A Critical Review
TL;DR:
Journal ArticleDOI
Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH.
Sunil Kumar,Parth Sarthi,Indra Mani,Muhammad Umer Ashraf,Myeong-Ho Kang,Vishal Kumar,Yong-Soo Bae +6 more
TL;DR: In this article, the authors proposed to improve the efficacy of ICB-therapy by co-targeting molecular checkpoints especially N6A-modification machineries which can be reformed into RNA modifying drugs (RMD).
Journal ArticleDOI
Interplay Between m6A RNA Methylation and Regulation of Metabolism in Cancer
TL;DR: It is hypothesized that m6A modification could dysregulate the expression of glucose, lipid, amino acid metabolism, and other metabolites or building blocks of cells by adaptation to the hypoxic tumor microenvironment, an increase in glycolysis, mitochondrial dysfunction, and abnormal expression of metabolic enzymes, metabolic receptors, transcription factors as well as oncogenic signaling pathways in both hematological malignancies and solid tumors.
References
More filters
Journal ArticleDOI
DNA methyltransferases: emerging targets for the discovery of inhibitors as potent anticancer drugs.
TL;DR: A structure-based overview of the therapeutic importance of DNMTs against different cancer types is provided, and recently investigated DNMTis as well as their inhibitory mechanisms are summarized, focusing on recent advances in the development ofDNMTis with specificity and/or selectivity developed through computational approaches.
Journal ArticleDOI
Chemical inhibitors make their RNA epigenetic mark
TL;DR: RNA epigenetic drug development enters a new era, as companies start revealing targets and evidence of preclinical efficacy and targets for new drugs are revealed.
Journal ArticleDOI
miR-150 exerts antileukemia activity in vitro and in vivo through regulating genes in multiple pathways.
Zhihong Fang,Si Li Wang,Jin Tao Zhao,Zhi Juan Lin,Lin Yan Chen,Rui Su,Si Ting Xie,Bing Z. Carter,Bing Xu +8 more
TL;DR: It is found that miR-150 is downregulated in samples from patients with acute lymphoblastic leukemia, acute myeloids leukemia, and chronic myeloid leukemia,and normalized after patients achieved complete remission, and provides a rationale for utilizing mi R-150 as a novel therapeutic agent for leukemia treatment.
Journal ArticleDOI
ADAR1: A New Target for Immuno-oncology Therapy.
TL;DR: Three recent studies show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointingADAR1 as a new immuno-oncology target.
Journal ArticleDOI
All-trans retinoic acid in the treatment of pediatric acute promyelocytic leukemia.
Riccardo Masetti,Francesca Vendemini,Daniele Zama,Carlotta Biagi,Pietro Gasperini,Andrea Pession +5 more
TL;DR: The introduction of ATRA in conjunction with anthracyclines marked a turning point in the treatment of APL, previously associated with a significant morbidity and mortality, and nowadays the standard front-line therapy for pediatric APL includes ATRAIn every phase of the treatment, resulting in a complete remission rate of 90–95%.
Related Papers (5)
Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development
Chiou-Tsun Tsai,Chi Wai Eric So +1 more
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber,Junwei Shi,Junwei Shi,Eric Wang,Amy R. Rappaport,Amy R. Rappaport,Harald Herrmann,Edward Allan R. Sison,Daniel Magoon,Jun Qi,Katharina Blatt,Mark Wunderlich,Meredith J. Taylor,Christopher Johns,Agustin Chicas,James C. Mulloy,Scott C. Kogan,Patrick Brown,Peter Valent,James E. Bradner,Scott W. Lowe,Scott W. Lowe,Scott W. Lowe,Christopher R. Vakoc +23 more